Company news

Esperion Therapeutics, Inc. news in 2025

Esperion Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes

December 19, 2025

Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

November 21, 2025

Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference

November 19, 2025

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

November 18, 2025

Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025

November 10, 2025

Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update

November 6, 2025

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

November 4, 2025

Esperion to Participate in Jefferies Global Healthcare Conference - London

November 3, 2025

Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2: 00 p.m. ET.

October 28, 2025

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

October 27, 2025

Esperion to Report Third Quarter 2025 Financial Results on November 6

October 23, 2025

Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis

October 16, 2025

Esperion Announces Pricing of Public Offering of Common Stock

October 7, 2025

Esperion Announces Proposed Public Offering of Common Stock

October 7, 2025

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040

October 3, 2025

Oritain Extends Cutting-Edge Origin Verification to Leather for EUDR Readiness

September 23, 2025

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

September 19, 2025

Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

August 29, 2025

Esperion to Participate in Upcoming September Investor Conferences

August 26, 2025

HLS Therapeutics Announces Q2 2025 Financial Results

August 14, 2025

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

August 5, 2025

Esperion to Report Second Quarter 2025 Financial Results on August 5

July 22, 2025

Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

July 8, 2025

Esperion Appoints Craig Thompson to Board of Directors

July 1, 2025

Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

June 2, 2025

Esperion to Participate in Upcoming June Investor Conferences

May 20, 2025

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

May 12, 2025

Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference

May 9, 2025

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

May 8, 2025

Esperion Reports First Quarter 2025 Financial Results

May 6, 2025

Esperion to Participate in The Citizens Life Sciences Conference

April 25, 2025

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

April 24, 2025

Esperion to Report First Quarter 2025 Financial Results on May 6

April 23, 2025

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

April 10, 2025

Esperion Appoints Robert E. Hoffman to Board of Directors

April 1, 2025

Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference

March 24, 2025

Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia

March 20, 2025

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

March 4, 2025

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

March 3, 2025

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

February 18, 2025

Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11: 30 a.m. ET.

January 8, 2025

Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference

January 1, 2025

Calls in 2025

Decks in 2025